(Q43031818)

12 November 2017

title

Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

Lee SS

1

1 reference

12 November 2017

Sherman M

series ordinal

2

1 reference

12 November 2017

publication date

1 May 2001

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

8

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

202-205

1 reference

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

Treatment of patients with chronic hepatitis C and normal ALT levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

An infectious molecular clone of a Japanese genotype 1b hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

Changes in hepatitis C virus quasispecies and density populations in patients before and after interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00286.X

10.1046/J.1365-2893.2001.00286.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference